Middle East Military Vehicles Market Outlook Report 2025-2030 Featuring Analysis of 15 Major Players, Including Rostec, Lockheed Martin Corporation, The Boeing Company, Abu Dhabi Ship Building Co., and IAI
Armored Vehicles Segment to Witness the Highest Growth. Turkey to Dominate Market Share.
Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Middle East Military Vehicles - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025-2030)" report has been added to ResearchAndMarkets.com's offering.The Middle East Military Vehicles Market size is estimated at USD 34.25 billion in 2025, and is expected to reach USD 46.49 billion by 2030, at a CAGR of 6.3% during the forecast period (2025-2030).While countries like Saudi Arabia, Israel, and the United Arab Emirates operate modern military vehicles, several countries in the region possess Soviet-era vehicles that require modernization. Hence, these countries are investing in the procurement of new military vehicles.In addition, the aging fleet of military vehicles is also forcing some countries to invest in upgrade programs to improve the efficiency, lethality, and sophistication of the vehicles if they are slated to be effectively functional for some more years.While the modernization and expansion of the region's vehicle fleets continue at a healthy pace, the region is also becoming increasingly self-sufficient and independent of foreign countries by developing indigenous manufacturing capabilities. Several countries have been developing military vehicles on their own or are partnering with their foreign counterparts and manufacturing vehicles locally with the help of technology transfer agreements.However, factors like fluctuations in oil prices are affecting the economies of several countries in Middle East, in turn affecting growth in military spending.
The Middle East military vehicles market is semi-consolidated and is marked by the presence of several local and international players vying for a larger market share. Some of the prominent players include Rostec, Lockheed Martin Corporation, The Boeing Company, Saudi Arabian Military Industries (SAMI), and Leonardo S.p.A.The growing focus on indigenous manufacturing of military vehicles is anticipated to increase the market share of local players during the forecast period. Countries like Turkey, Saudi Arabia, and the United Arab Emirates are the frontrunners in indigenous manufacturing. For instance, Saudi Arabia is focused on enhancing its defense weapon and ammunition manufacturing capability to reduce its dependency on the export of military equipment and weapons in line with the Saudi government's Vision 2030. The government plans to increase the local military equipment spending to 50% by 2030. Saudi Arabian Military Industries (SAMI), BMC Otomotiv Sanayi ve Ticaret AS, and Denel SOC Ltd are prominent local manufacturers.Middle East Military Vehicles Market Trends
Armored Vehicles Segment to Witness Highest Growth During the Forecast PeriodOver the past few years, the military equipment procurement of the region increased at a rapid pace, due to the conflicts in Yemen, Libya, and Somalia and the Sinai insurgency.UAE plans to modernize all units of the UAE armed forces with new and advanced military equipment to continue developing capabilities. For instance, in February 2023, Nexter, the leading French land defense company, signed a teaming agreement with International Golden Group, the leading supplier of the UAE Armed forces, to prepare for the modernisation of the UAE Army's Leclerc main battle tank (MBT).The UAE also intends to utilize the MRAP vehicles to increase force protection, conduct humanitarian assistance operations, and protect critical infrastructure. In February 2023, the first batch of 400 Rabdan 8x8 infantry fighting vehicles (IFVs) was delivered to the UAE Army and manufacturer Otokar is hopeful that additional orders will be placed in the future.Iran has a very large fleet of wheeled and sand-blasted armored vehicles that can be equipped to carry out missions such as fire support by making a series of modifications. For example, BTR 50 and 60 series and BMP 1 and 2 personnel carriers are among these armored vehicles. Such robust plans of the government of countries in Middle East to rapidly increase the fleet of armored vehicles are anticipated to propel the growth of the military vehicles market in the coming years.Turkey to Dominate Market Share During the Forecast PeriodTurkey has been significantly investing in its defense industry and expanding production. The recent focus on domestic design and production stems from an increase in potential threats from Russia and various militant groups and from sanctions placed on Turkey's defense industry by its NATO allies. In this context, in May 2023, Turkey's FNSS Defence Systems was contracted to provide capability enhancement to the Turkish Army's ACV-15 advanced armored personnel carriers (AAPCs). The agreement was signed to boost the vehicle's performance and extend its service life for an additional 20 years. According to the company, an undisclosed number of AAPCs will be fitted with modern subsystems to support more missions and help address sophisticated threats on the battlefield.Turkey's procurement and defense authorities have launched a program designed to increase the structural life of the country's existing fleet of F-16 Block 30 jets from 8,000 flight hours to 12,000. The upgrades may cover 1,200 to 1,500 parts per aircraft.In addition, Turkey has vastly advanced in armored vehicle manufacturing and is acquiring new vehicles to modernize its fleet and with its interest in upgrading its naval fleet to further contribute to the growth of the market. For instance, in April 2023, the Turkish Navy received its largest vessel, the amphibious assault ship TCG Anadolu which is Turkey's first landing platform dock. The military will deploy heavy helicopters, drones and light-attack aircraft from the vessel.Key Topics Covered1 INTRODUCTION1.1 Study Assumptions and Market Definition1.2 Scope of the Study1.3 Currency Conversion Rates for USD2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.3 Market Restraints4.4 Porter's Five Forces Analysis4.4.1 Bargaining Power of Buyers/Consumers4.4.2 Bargaining Power of Suppliers4.4.3 Threat of New Entrants4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry5 MARKET SEGMENTATION 5.1 Military Aircraft5.1.1 Combat Aircraft5.1.1.1 Fighter Aircraft5.1.1.2 Combat Helicopters5.1.2 Non-combat Aircraft5.1.2.1 Reconnaissance and Surveillance Aircraft5.1.2.2 Trainer Aircraft5.1.2.3 Transport Aircraft5.1.2.4 Other Non-combat Aircraft5.2 Naval Vessels5.2.1 Destroyers5.2.2 Frigates5.2.3 Corvettes5.2.4 Submarines5.2.5 Other Naval Vessels5.3 Armored Vehicles5.3.1 Armored Personnel Carriers5.3.2 Infantry Fighting Vehicles5.3.3 Mine-Resistant Ambush Protected5.3.4 Main Battle Tanks5.3.5 Other Armored Vehicles5.4 Geography5.4.1 Saudi Arabia5.4.2 United Arab Emirates5.4.3 Qatar5.4.4 Turkey5.4.5 Israel5.4.6 Rest of the Middle East6 COMPETITIVE LANDSCAPE6.1 Vendor Market Share6.2 Company Profiles6.2.1 Rostec6.2.2 Lockheed Martin Corporation6.2.3 The Boeing Company6.2.4 Abu Dhabi Ship Building Co.6.2.5 IAI6.2.6 BMC Otomotiv Sanayi ve Ticaret A.S.6.2.7 Fincantieri S.p.A.6.2.8 Saudi Arabian Military Industries (SAMI)6.2.9 Dassault Aviation SA6.2.10 Naval Group6.2.11 Denel SOC Ltd.6.2.12 BAE Systems plc6.2.13 Oshkosh Corporation6.2.14 Airbus SE6.2.15 Leonardo S.p.A.6.2.16 Patria Group6.2.17 FNSS Savunma Sistemleri A.S.7 MARKET OPPORTUNITIES AND FUTURE TRENDSFor more information about this report visit https://www.researchandmarkets.com/r/orl406
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
XSQUARE Technologies and Alkhorayef Commercial Company Sign MoU to Advance Saudi Arabia's Logistics Landscape
SINGAPORE, June 2, 2025 /PRNewswire/ -- Singapore-based XSQUARE Technologies and Alkhorayef Commercial Company (ACC), a leading integrated commercial and industrial solutions provider in the Kingdom of Saudi Arabia, have signed a Memorandum of Understanding (MoU) to establish a strategic framework for collaboration aimed at accelerating the adoption of intelligent warehouse automation and transforming intralogistics operations across Saudi Arabia. The signing took place at the Saudi Warehousing & Logistics Expo 2025. The MoU seeks to integrate ACC's growing logistics capabilities and XSQUARE's next-generation intelligent warehouse automation solutions – comprising a suite of Autonomous Mobile Robots (AMRs) and a warehouse orchestration software – to deliver a high-performance, safe, and scalable intralogistics solutions for the Saudi market. Under the agreement, both companies will collaborate on joint market outreach and the deployment of customisable end-to-end automation solutions across key logistics and industrial hubs. The partnership will also include the development of pilot projects and demonstrations to showcase the operational efficiencies and economic benefits of AMR-enabled logistics. Fahad AlJaddan, CEO of Alkhorayef Commercial Company, commented: "This partnership marks a significant step forward in our journey to shape the future of logistics in Saudi Arabia. By working with XSQUARE Technologies, we are bringing cutting-edge automation into our ecosystem and empowering our customers with solutions that are efficient, intelligent, and built for scale. We look forward to advancing Saudi Arabia's logistics landscape in support of Vision 2030's agenda." As part of its commitments, ACC will leverage its strong local presence and logistics expertise to support the deployment of XSQUARE's automation technologies. This includes promoting AMRs as solutions to key customers and providing commercial insights to guide market adaptation. XSQUARE Technologies, in turn, will provide technical enablement and integration support, including training, product documentation, and solution roadmaps. The company will also provide access to dedicated experts to support localisation efforts and execute pilot projects. Jens Bohnwagner, CEO of XSQUARE Technologies, commented:"Partnering with ACC will allow us to bring our proven automation technologies into a rapidly evolving market with immense potential. As a respected leader in the region's logistics sector with deep market knowledge and operational excellence, ACC is an ideal partner in our journey. We see this collaboration as a powerful platform to demonstrate both the impact and adaptability of our warehouse automation solutions to the specific demands of Saudi Arabia and the region." The MoU is a clear demonstration of both companies' shared commitment to a long-term partnership dedicated to driving the transformation of Saudi Arabia's logistics sector through innovation and adaptability. About XSQUARE Technologies XSQUARE Technologies is at the forefront of the logistics revolution, offering cutting-edge warehouse automation solutions across Asia Pacific and beyond. Backed by Goldbell Group's 40 years of expertise, we offer a suite of Autonomous Forklifts and Intelligent Warehouse Orchestrator software that set new standards in interoperability and efficiency, simplifying warehouse operations without the need for extensive reconfiguration and thus saving time and costs. Spanning a diverse range of industries from pharmaceuticals to manufacturing, we have a rapidly growing clientele that benefits from our innovation-driven, real-world-tested solutions. Visit to learn more. About Alkhorayef Commercial Company (ACC) Alkhorayef Commercial (ACC), established in 1957, is a provider of integrated industrial solutions across key sectors, including agriculture, logistics, marine, and entertainment in Saudi Arabia. Through partnerships with global brands, ACC supplies high-quality products and comprehensive aftersales services to enhance efficiency, reliability, and sustainability. Visit to learn more. View original content to download multimedia: SOURCE XSQUARE Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
6 hours ago
- Yahoo
Electric Motors Market Share Expected to Grow $206.4 Billion by 2029
Delray Beach, FL, June 01, 2025 (GLOBE NEWSWIRE) -- The global Electric Motors Market share is expected to grow from USD 152.2 billion in 2024 to USD 206.4 billion by 2029, at a CAGR of 6.3% during forecast period. Electric motors market is driven mainly by Increasing demand for HVAC systems among residential, commercial, and industrial end-users, growing demand for electric motors in manufacturing industries, and rising demand for energy-efficient motors. The electric motor market has bloomed forth globally. All these sectors inherit demanding environments for solving problems and improving reliability. From electric vehicles to industrial machinery, consumer electronics to wind turbines, electric motors find applications in many areas. They not only ensure low energy consumption but also increase efficiency and reduce operating costs. As the world population grows and economies expand, the demand for energy, particularly oil and gas, continues to rise. Increasing demand for HVAC (Heating, Ventilation, and Air Conditioning) systems among residential, commercial, and industrial end-users, industries shift towards energy-efficient electric motors due to lowered energy utilization and operational costs in manufacturing industries are some of the major driving factors for the electric motors market. Download PDF Brochure: List of Key Players in Electric Motors Market: ABB (Switzerland) Siemens (Germany) WEG (Brazil) Wolong Electric (China) NIDEC CORPORATION (Japan) Drivers, Opportunities and Challenges in Electric Motors Market: Driver: Increasing demand for HVAC systems in residential, commercial, and industrial sectors Restraint: Fluctuating prices of raw materials Opportunity: Transition in the global automotive industry toward electric vehicles Challenge: Shortage of components and supply chain issues Electric mobility is making a huge transition in the global automobile industry. The proactive efforts for the decarbonization of society in Europe are driven by the ever-increasing share of electric motors in the market. Advancements in battery technologies have reduced costs of batteries and improved the charging speed of the batteries. The increase in government support by providing redemptions on tax and incentives for promoting eco-friendly electric vehicles through electric motors are also acts of opportunities for the growth of the electric motors market. As per the IEA, it is revealed that 50% of global passenger electric vehicles should come from China in the year 2025. Many governments worldwide are implementing policies and incentives to promote the adoption of electric vehicles as part of efforts to reduce greenhouse gas emissions and combat climate change. These policies include subsidies for EV purchases, tax incentives, and stricter emissions regulations, all of which are accelerating the transition to electric mobility and, consequently, increasing demand for electric vehicle motor market. The rapid growth of the EV market has led to the construction of new manufacturing facilities dedicated to producing electric vehicles and their components, including electric motors. Major automakers and new EV startups are investing heavily in scaling up production, which includes securing a reliable supply of electric motors. the growing demand for electric vehicles is a major driver of demand for electric motors. The transition to electric mobility, driven by technological advancements, government policies, and consumer preferences, is creating a significant and expanding market for electric motors across a wide range of vehicle types and applications. As the EV market continues to grow, the demand for efficient, powerful, and innovative electric motors will remain strong.. Request Sample Pages: Asia Pacific region to be the largest electric motors market Asia Pacific is expected to dominate the global electric motor market size between 2024–2029, followed by Europe and North America. The urban population growth drives demand for infrastructure, including commercial buildings, residential complexes, and public utilities, all of which rely heavily on electric motors for HVAC systems, elevators, water treatment, etc are the reasons for the region's significant market size. Countries such as China and India are driving demand, supported by government initiatives promoting industrial automation and renewable energy adoption. The region's large water treatment plants and increasing electric vehicle manufacturing add to the demand for high-power motors. Moreover, improving motor efficiency and compact high-density designs also increase the market further. This is driving the electric motor market size in the Asia Pacific region. Related Reports: Brushless DC Motor Market - Global Forecast to 2028 Energy Efficient Motor Market - Global Forecast to 2028 CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website: